Professor, Psychiatry, University of Pittsburgh School of Medicine
Psychiatry
Dr. William E. Klunk, MD
|
|
Give Review
William Klunk practices Psychiatry. He attended Washington University School of Medicine in St. Louis. William E. Klunk is also published. He has 81 publications published. The lastest publication: "Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?'
Publications
- Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?
- Partial volume correction in quantitative amyloid imaging.
- The centiloid project: Standardizing quantitative amyloid plaque estimation by PET.
- Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects.
- Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.
- Arterial Stiffness and β-Amyloid Progression in Nondemented Elderly Adults.
- Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
- Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis.
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.
- Amyloid burden and neural function in people at risk for Alzheimer's Disease.
- Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial.
- Markers of cholesterol transport are associated with amyloid deposition in the brain.
- Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture.
- Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
- Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.
- In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.
- Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.
- Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease.
- Positron emission tomography radioligands for in vivo imaging of Aβ plaques.
- Disclosure of amyloid imaging results to research participants: Has the time come?
- Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches.
- Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
- Amyloid imaging as a biomarker for cerebral ?-amyloidosis and risk prediction for Alzheimer dementia.
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab.
- Anomalous PiB enhancement in the Superior Sagittal and Transverse Venous Sinuses.
- Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines ...
- Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.
- In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
- Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.
- Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.
- Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case...
- Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.
- Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
- PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET.
- Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
- Amyloid imaging in mild cognitive impairment subtypes.
- Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.
- Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
- Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
- Frequent amyloid deposition without significant cognitive impairment among the elderly.
- Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
- Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?
- Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.
- Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
- Whatever happened to Pittsburgh Compound-A?
- Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.
- Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
- Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
- Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
- Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
- Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
- Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
- X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.
- The role of biomarkers in clinical trials for Alzheimer disease.
- Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
- Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse b...
- Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex.
- Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.
- Commentary on "Diagnosis of Alzheimer's disease: two decades of progress." Diagnosis of Alzheimer's disease: walking a well-paved path.
- Role of biomarkers in studies of presymptomatic Alzheimer's disease.
- Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
- Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies.
- Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.
- Targeting prion amyloid deposits in vivo.
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
- Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
- Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.
- Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.
- Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
- The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.
- Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
- Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives.
- Imaging amyloid-beta deposits in vivo.
- Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative.
- Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease.
- Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology.
- Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?
Schools
Washington Center School of Medicine
Doctors Specialties
- Geriatric Psychiatry
- Psychiatry
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
Washington University School of Medicine in St. Louis
Hospital
-
UPMC Presbyterian Shadyside
Helpful Reviews
Similar Doctors
|
|
Dr. Harvey D. Shipkovitz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maurice S. Cerul, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary Vallano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne R. Capdeville, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jagdeep K. Bajwa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mandayam C. Sujata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madhavan Thuppal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadeem Ahmed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon A. Altman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marie A. Gebara, MD |
|
|
Dr. Rajkumar R. Sarma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Travis, MD |
|
|
Dr. Lalithkumar Solai, MD |
|
|
Dr. David W. Volk, MD
This Doctor is OpenDoctor Recommended.
|